Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission

Wei, Andrew H.; Döhner, Hartmut; Pocock, Christopher; Montesinos, Pierre; Afanasyev, Boris V.; Dombret, Herve; Ravandi, Farhad; Sayar, Hamide; Jang, Jun-Ho; Porkka, K.; Selleslag, Dominik; Sandhu, Inderpreet Singh; Turgut, Murat; Giai, Valentina; Ofran, Yishay; Cakar, M. Kizil; de Sousa, A. Botelho; Rybka, J.; Frairia, Chiara; Borin, Lucileni Aparecida; Beltrami, Gianfranco; Cermak, Joshua A.; Ossenkoppele, Gert; La Torre, I.; Skikne, Barry; Kumar, K.; Dong, Q.; Beach, Charles L.; Roboz, Gail J.; QUAZAR AML 001 Trial Investigators

Erstveröffentlichung

2020

Metadata only
Search for full text

Wissenschaftlicher Artikel

Authors

Wei, Andrew H.

Döhner, Hartmut

Pocock, Christopher

Montesinos, Pierre

Afanasyev, Boris V.

et al.

Institutions

UKU. Klinik für Innere Medizin III

Published in

The New England Journal of Medicine ; 383 (2020), 26. - S. 2526-2537. - ISSN 0028-4793. - eISSN 1533-4406

Link to publication

https://dx.doi.org/10.1056/NEJMoa2004444

Keywords

RISK MYELODYSPLASTIC SYNDROMES; CONVENTIONAL CARE REGIMENS; TREATMENT OUTCOMES; RESIDUAL DISEASE; YOUNGER ADULTS; OLDER PATIENTS; GROUP-B; AML; CHEMOTHERAPY; AZACYTIDINE

Dewey Decimal Group

DDC 610 / Medicine & health

Metadata

Show full item record